The Institute of Cancer Research’s recent report on innovative cancer therapies and access to such drugs suggests that the National Institute for Health and Care Excellence’s efforts to reduce the time to patient has to date been insufficient.
According to Pink Sheet, the report also says the European Medicines Agency should consider adopting some strategies used by the U.S. Food and Drug Administration.
Click here to read the full report on Pink Sheet. (Paid subscription required)
